BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38081549)

  • 1. Micafungin twice-a-week for prophylaxis of invasive Aspergillus infections in children with acute lymphoblastic leukaemia: A controlled cohort study.
    Bury D; Wolfs TFW; Muilwijk EW; Fiocco M; Pieters R; Brüggemann RJ; Tissing WJE
    Int J Antimicrob Agents; 2024 Jan; 63(1):107058. PubMed ID: 38081549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic evaluation of twice-a-week micafungin for prophylaxis of invasive fungal disease in children with acute lymphoblastic leukaemia: a prospective observational cohort study.
    Bury D; Wolfs TFW; Ter Heine R; Muilwijk EW; Tissing WJE; Brüggemann RJ
    J Antimicrob Chemother; 2022 Feb; 77(3):699-703. PubMed ID: 34939125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study.
    Yamaguchi M; Kurokawa T; Ishiyama K; Aoki G; Ueda M; Matano S; Takami A; Yamazaki H; Sawazaki A; Yamauchi H; Yoshida T; Nakao S
    Ann Hematol; 2011 Oct; 90(10):1209-17. PubMed ID: 21695388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
    Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
    J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micafungin as antifungal prophylaxis in non-transplanted haemotological patients.
    Villaescusa T; Vázquez L; Bergua JM; García J; Romero A; Olave MT; García Belmonte D; Queipo de Llano MP;
    Rev Esp Quimioter; 2020 Feb; 33(1):44-48. PubMed ID: 31865649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.
    Yeh TC; Liu HC; Hou JY; Chen KH; Huang TH; Chang CY; Liang DC
    Cancer; 2014 Apr; 120(8):1255-62. PubMed ID: 24415457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of micafungin in pediatric immunocompromised patients with invasive fungal infection.
    Hashii Y; Kusuki S; Takizawa S; Tokimasa S; Ohta H; Hara J; Ozono K
    Pediatr Int; 2014 Dec; 56(6):834-837. PubMed ID: 24730676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.
    Park H; Youk J; Shin DY; Hong J; Kim I; Kim NJ; Lee JO; Bang SM; Yoon SS; Park WB; Koh Y
    BMC Cancer; 2019 Apr; 19(1):358. PubMed ID: 30991992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary antifungal prophylaxis with micafungin in patients with haematological malignancies: real-life data from a retrospective single-centre observational study.
    Nachbaur D; Angelova O; Orth-Höller D; Ditlbacher A; Lackner M; Auberger J; Lass-Flörl C
    Eur J Haematol; 2015 Mar; 94(3):258-64. PubMed ID: 25082655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant.
    Huang X; Chen H; Han M; Zou P; Wu D; Lai Y; Huang H; Chen X; Liu T; Zhu H; Wang J; Hu J
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1509-16. PubMed ID: 22469884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.
    Denning DW; Marr KA; Lau WM; Facklam DP; Ratanatharathorn V; Becker C; Ullmann AJ; Seibel NL; Flynn PM; van Burik JA; Buell DN; Patterson TF
    J Infect; 2006 Nov; 53(5):337-49. PubMed ID: 16678903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of micafungin for the treatment of patients with proven or probable invasive aspergillosis: A non-comparative, multicenter, phase IV, open-label study.
    Ji Y; Song Y; Zhou F; Liu T; Jiang M; Zhao X; Huang X
    Medicine (Baltimore); 2017 Dec; 96(52):e9443. PubMed ID: 29384927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micafungin use in children.
    Emiroglu M
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):821-34. PubMed ID: 21905789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease.
    Bochennek K; Balan A; Müller-Scholden L; Becker M; Farowski F; Müller C; Groll AH; Lehrnbecher T
    J Antimicrob Chemother; 2015 May; 70(5):1527-30. PubMed ID: 25564562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT.
    El-Cheikh J; Venton G; Crocchiolo R; Fürst S; Faucher C; Granata A; Oudin C; Coso D; Bouabdallah R; Vey N; Duran S; Fougereau E; Berger P; Chabannon C; Blaise D
    Bone Marrow Transplant; 2013 Nov; 48(11):1472-7. PubMed ID: 23749104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA
    Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Efficacy and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant Recipients: A Retrospective Analysis.
    Maximova N; Schillani G; Simeone R; Maestro A; Zanon D
    Adv Ther; 2017 May; 34(5):1184-1199. PubMed ID: 28429246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi].
    Salavert-Lletí M; Zaragoza-Crespo R
    Rev Iberoam Micol; 2009 Mar; 26(1):81-9. PubMed ID: 19463284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network.
    Lockhart SR; Zimbeck AJ; Baddley JW; Marr KA; Andes DR; Walsh TJ; Kauffman CA; Kontoyiannis DP; Ito JI; Pappas PG; Chiller T
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3944-6. PubMed ID: 21670187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.
    Carter NJ; Keating GM
    Paediatr Drugs; 2009; 11(4):271-91. PubMed ID: 19566111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.